Helicobacter pylori is a Gram-negative, spiral bacterium that colonizes the gastric mucosa of at least 50% of the world’s population and plays a causative role in the development of chronic gastritis as well as in gastric and duodenal ulcers. H. pylori triggers vigorous humoral and cellular immune responses in both systemic and mucosal compartments. In spite of this response, the vast majority of infected hosts are unable to clear the infection, and it persists for decades. Although Helicobacter is tolerated by a naïve host organism, preclinical studies have demonstrated that prophylactic or therapeutic vaccinations efficiently clear Helicobacter from the stomach. The understanding of the mechanisms leading to the Helicobacter persistence or the vaccine-induced eradication of Helicobacter in animal models will help to define optimal immunization strategies for future anti-Helicobacter vaccination clinical trials.

1.
Feldman RA: Epidemiologic observations and open questions about disease and infection caused by Helicobacter pylori; in Achtman M, Suerbaum S (eds): Helicobacter pylori: Molecular and Cellular Biology. Wymondham, Horizon Scientific Press, 2001, pp 29–51.
2.
Malaty HM, Graham DY: Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut 1994;35:742–745.
[PubMed]
3.
Rowland M, Kumar D, Daly L, O’Connor P, Vaughan D, Drumm B: Low rates of Helicobacter pylori reinfection in children. Gastroenterology 1999;117:336–341.
[PubMed]
4.
Parsonnet J, Shmuely H, Haggerty T: Fecal and oral shedding of Helicobacter pylori from healthy infected adults. JAMA 1999;282:2240–2245.
[PubMed]
5.
Goodman KJ, Correa P, Tengana Aux HJ, Ramirez H, DeLany JP, Guerrero PO, Lopez QM, Collazos PT: Helicobacter pylori infection in the Colombian Andes: a population-based study of transmission pathways. Am J Epidemiol 1996;144:290–299.
[PubMed]
6.
Correa P: Human gastric carcinogenesis: a multistep and multifactorial process – First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735–6740.
[PubMed]
7.
Ernst PB, Gold BD: The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu Rev Microbiol 2000;54:615–640.
[PubMed]
8.
Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784–789.
[PubMed]
9.
Zucca E, Bertoni F, Roggero E, Bosshard G, Cazzaniga G, Pedrinis E, Biondi A, Cavalli F: Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. N Engl J Med 1998;338:804–810.
[PubMed]
10.
Marshall B, Warren JR: Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;i:1311–1315.
[PubMed]
11.
Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ: Attempt to fulfil Koch’s postulates for pyloric Campylobacter. Med J Aust 1985;142:436–439.
[PubMed]
12.
Megraud F: A humble bacterium sweeps this year’s Nobel Prize. Cell 2005;123:975–976.
[PubMed]
13.
Kavermann H, Burns BP, Angermuller K, Odenbreit S, Fischer W, Melchers K, Haas R: Identification and characterization of Helicobacter pylori genes essential for gastric colonization. J Exp Med 2003;197:813–822.
[PubMed]
14.
Guo BP, Mekalanos JJ: Rapid genetic analysis of Helicobacter pylori gastric mucosal colonization in suckling mice. Proc Natl Acad Sci USA 2002;99:8354–8359.
[PubMed]
15.
Blaser MJ, Atherton JC: Helicobacter pylori persistence: biology and disease. J Clin Invest 2004;113:321–333.
[PubMed]
16.
Israel DA, Salama N, Arnold CN, Moss SF, Ando T, Wirth HP, Tham KT, Camorlinga M, Blaser MJ, Falkow S, Peek RM Jr: Helicobacter pylori strain-specific differences in genetic content, identified by microarray, influence host inflammatory responses. J Clin Invest 2001;107:611–620.
[PubMed]
17.
Dooley CP, Cohen H, Fitzgibbons PL, Bauer M, Appleman MD, Perez-Perez GI, Blaser MJ: Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. N Engl J Med 1989;321:1562–1566.
[PubMed]
18.
Goodwin CS: Campylobacter pyloridis, gastritis, and peptic ulceration. J Clin Pathol 1986;39:353–365.
[PubMed]
19.
Segal ED, Cha J, Lo J, Falkow S, Tompkins LS: Altered states: involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori. Proc Natl Acad Sci USA 1999;96:14559–14564.
[PubMed]
20.
Amieva MR, Vogetmann R, Covacci A, Tompkins LS, Nelson WJ, Falkow S: Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA. Science 2003;300:1430–1434.
[PubMed]
21.
Naumann M, Crabtree JE: Helicobacter pylori-induced epithelial cell signalling in gastric carcinogenesis. Trends Microbiol 2004;12:29–36.
[PubMed]
22.
Peek RM Jr: IV. Helicobacter pylori strain-specific activation of signal transduction cascades related to gastric inflammation. Am J Physiol Gastrointest Liver Physiol 2001;280:G525–G530.
23.
Moss SF, Sordillo EM, Abdalla AM, Makarov V, Hanzely Z, Perez-Perez GI, Blaser MJ, Holt PR: Increased gastric epithelial cell apoptosis associated with colonization with cagA+ Helicobacter pylori strains. Cancer Res 2001;61:1406–1411.
[PubMed]
24.
Cox JM, Clayton CL, Tomita T, Wallace DM, Robinson PA, Crabtree JE: cDNA array analysis of cag pathogenicity island-associated Helicobacter pylori epithelial cell response genes. Infect Immun 2001;69:6970–6980.
[PubMed]
25.
Yamaoka Y, Kita M, Kodama T, Sawai N, Imanishi J: Helicobacter pylori cagA gene and expression of cytokine messenger RNA in gastric mucosa. Gastroenterology 1996;110:1744–1752.
[PubMed]
26.
Yamaoka Y, Kita M, Kodama T, Sawai N, Kashima K, Imanishi J: Induction of various cytokines and development of severe mucosal inflammation by cagA gene positive Helicobacter pylori strains. Gut 1997;41:442–451.
[PubMed]
27.
Crabtree JE, Wyatt JI, Trejdosiewicz LK, Peichl P, Nichols PH, Ramsay N, Primrose JN, Lindley IJ: Interleukin-8 expression in Helicobacter pylori infected, normal, and neoplastic gastroduodenal mucosa. J Clin Pathol 1994;47:61–66.
[PubMed]
28.
Crabtree JE, Shallcross TM, Heatley RV, Wyatt JI: Mucosal tumour necrosis factor alpha and interleukin-6 in patients with Helicobacter pylori associated gastritis. Gut 1991;32:1473–1477.
[PubMed]
29.
Macarthur M, Hold GL, El-Omar EM: Inflammation and cancer. 2. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 2004;286:G515–G520.
30.
Nagata K, Yu H, Nishikawa M, Kashiba M, Nakamura A, Sato EF, Tamura T, Inoue M: Helicobacter pylori generates superoxide radicals and modulates nitric oxide metabolism. J Biol Chem 1998;273:14071–14073.
[PubMed]
31.
Perez-Perez GI, Dworkin BM, Chodos JE, Blaser MJ: Campylobacter pylori antibodies in humans. Ann Intern Med 1988;109:11–17.
[PubMed]
32.
Valnes K, Brandtzaeg P, Elgjo K, Stave R: Quantitative distribution of immunoglobulin-producing cells in gastric mucosa: relation to chronic gastritis and glandular atrophy. Gut 1986;27:505–514.
[PubMed]
33.
Berstad AE, Brandtzaeg P, Stave R, Halstensen TS: Epithelium related deposition of activated complement in Helicobacter pylori associated gastritis. Gut 1997;40:196–203.
[PubMed]
34.
Negrini R, Savio A, Appelmelk BJ: Autoantibodies to gastric mucosa in Helicobacter pylori infection. Helicobacter 1997;2(suppl 1):S13–S16.
35.
Hatz RA, Meimarakis G, Bayerdorffer E, Stolte M, Kirchner T, Enders G: Characterization of lymphocytic infiltrates in Helicobacter pylori-associated gastritis. Scand J Gastroenterol 1996;31:222–228.
[PubMed]
36.
Bamford KB, Fan X, Crowe SE, Leary JF, Gourley WK, Luthra GK, Brooks EG, Graham DY, Reyes VE, Ernst PB: Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T helper cell 1 phenotype. Gastroenterology 1998;114:482–492.
[PubMed]
37.
Harris PR, Smythies LE, Smith PD, Dubois A: Inflammatory cytokine mRNA expression during early and persistent Helicobacter pylori infection in nonhuman primates. J Infect Dis 2000;181:783–786.
[PubMed]
38.
Gewirtz AT, Yu Y, Krishna US, Israel DA, Lyons SL, Peek RM Jr: Helicobacter pylori flagellin evades Toll-like receptor 5-mediated innate immunity. J Infect Dis2004;189:1914–1920.
[PubMed]
39.
Suda Y, Kim YM, Ogawa T, Yasui N, Hasegawa Y, Kashihara W, Shimoyama T, Aoyama K, Nagata K, Tamura T, Kusumuto S: Chemical structure and biological activity of a lipid A component from Helicobacter pylori strain 206. J Endotoxin Res 2001;7:95–104.
[PubMed]
40.
Akhiani AA, Schon K, Franzen LE, Pappo J, Lycke N: Helicobacter pylori-specific antibodies impair the development of gastritis, facilitate bacterial colonization, and counteract resistance against infection. J Immunol 2004;172:5024–5033.
[PubMed]
41.
Lindholm C, Quiding-Jarbrink M, Lonroth H, Hamlet A, Svennerholm AM: Local cytokine response in Helicobacter pylori-infected subjects. Infect Immun 1998;66:5964–5971.
[PubMed]
42.
Lundgren A, Suri-Payer E, Enarsson K, Svennerholm AM, Lundin BS: Helicobacter pylori-specific CD4+ CD25high regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. Infect Immun 2003;71:1755–1762.
[PubMed]
43.
Raghavan S, Fredriksson M, Svennerholm AM, Holmgren J, Suri-Payer E: Absence of CD4+CD25+ regulatory T cells is associated with a loss of regulation leading to increased pathology in Helicobacter pylori-infected mice. Clin Exp Immunol 2003;132:393–400.
[PubMed]
44.
Lundgren A, Stromberg E, Sjoling A, Lindholm C, Enarsson K, Edebo A, Johnsson E, Suri-Payer E, Larsson P, Rudin A, Svennerholm AM, Lundin BS: Mucosal FOXP3-expressing CD4+ CD25high regulatory T cells in Helicobacter pylori-infected patients. Infect Immun 2005;73:523–531.
[PubMed]
45.
Strobel S: Immunity induced after a feed of antigen during early life: oral tolerance v sensitisation. Proc Nutr Soc 2001;60:437–442.
[PubMed]
46.
Suerbaum S, Michetti P: Helicobacter pylori infection. N Engl J Med 2002;347:1175–1186.
[PubMed]
47.
Michetti P, Corthesy-Theulaz I, Davin C, Haas R, Vaney AC, Heitz M, Bille J, Kraehenbuhl JP, Saraga E, Blum AL: Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology 1994;107:1002–1011.
[PubMed]
48.
Weltzin R, Kleanthous H, Guirakhoo F, Monath TP, Lee C: Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection. Vaccine 1997;15:370–376.
[PubMed]
49.
Kleanthous H, Myers GA, Georgakopoulos KM, Tibbitts TJ, Ingrassia JW, Gray HL, Ding R, Zhang ZZ, Lei W, Nichols R, Lee CK, Ermak TH, Monath TP: Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect Immun 1998;66:2879–2886.
[PubMed]
50.
Cuenca R, Blanchard TG, Czinn SJ, Nedrud JG, Monath TP, Lee CK, Redline RW: Therapeutic immunization against Helicobacter mustelae in naturally infected ferrets. Gastroenterology 1996;110:1770–1775.
[PubMed]
51.
Dubois A, Lee C, Fiala N, Kleanthous H, Mehlman P, Monath TP: Immunization against natural Helicobacter pylori infection in nonhuman primates. Infect Immun 1998;66:4340–4346.
[PubMed]
52.
Lee C, Soike K, Giannasca P, Hill J, Weltzin R, Kleanthous H, Blanchard J, Monath TP: Immunization of rhesus monkeys with a mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori. Vaccine 1999;17:3072–3082.
[PubMed]
53.
Lee C, Soike K, Hill J, Georgakopoulos K, Tibbitts T, Ingrassia J, Gray H, Boden J, Kleanthous H, Giannasca P, Ermak TH, Weltzin R, Blanchard J, Monath TP: Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys. Vaccine 1999;17:1493–1505.
[PubMed]
54.
Del Giudice G, Covacci A, Telford JL, Montecucco C, Rappuoli R: The design of vaccines against Helicobacter pylori and their development. Annu Rev Immunol 2001;19:523–563.
[PubMed]
55.
Kreiss C, Buclin T, Cosma M, Michetti P: Safety of oral immunization with recombinant urease in patients with Helicobacter pylori infection. Lancet 1996;347:1630–1631.
[PubMed]
56.
Michetti P, Kreiss C, Kotloff KL, Porta N, Blanco JL, Bachmann D, Herranz M, Saldinger PF, Corthesy-Theulaz I, Losonsky G, Nichols R, Simon J, Stolte M, Ackerman S, Monath TP, Blum AL: Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 1999;116:804–812.
[PubMed]
57.
Banerjee S, Medina-Fatimi A, Nichols R, Tendler D, Michetti M, Simon J, Kelly CP, Monath TP, Michetti P: Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut 2002;51:634–640.
[PubMed]
58.
Sougioultzis S, Lee CK, Alsahli M, Banerjee S, Cadoz M, Schrader R, Guy B, Bedford P, Monath TP, Kelly CP, Michetti P: Safety and efficacy of E coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine 2002;21:194–201.
[PubMed]
59.
Gottwein JM, Blanchard TG, Targoni OS, Eisenberg JC, Zagorski BM, Redline RW, Nedrud JG, Tary-Lehmann M, Lehmann PV, Czinn SJ: Protective anti-Helicobacter immunity is induced with aluminum hydroxide or complete Freund’s adjuvant by systemic immunization. J Infect Dis 2001;184:308–314.
[PubMed]
60.
Pappo J, Torrey D, Castriotta L, Savinainen A, Kabok Z, Ibraghimov A: Helicobacter pylori infection in immunized mice lacking major histocompatibility complex class I and class II functions. Infect Immun 1999;67:337–341.
[PubMed]
61.
Ermak TH, Giannasca PJ, Nichols R, Myers GA, Nedrud J, Weltzin R, Lee CK, Kleanthous H, Monath TP: Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med 1998;188:2277–2288.
[PubMed]
62.
Aebischer T, Laforsch S, Hurwitz R, Brombacher F, Meyer TF: Immunity against Helicobacter pylori: significance of interleukin-4 receptor alpha chain status and gender of infected mice. Infect Immun 2001;69:556–558.
[PubMed]
63.
Sawai N, Kita M, Kodama T, Tanahashi T, Yamaoka Y, Tagawa Y, Iwakura Y, Imanishi J: Role of gamma interferon in Helicobacter pylori-induced gastric inflammatory responses in a mouse model. Infect Immun 1999;67:279–285.
[PubMed]
64.
Lee CK, Weltzin R, Thomas W Jr, Kleanthous H, Ermak TH, Soman G, Hill JE, Ackerman SK, Monath TP: Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J Infect Dis 1995;172:161–172.
[PubMed]
65.
Michetti M, Kelly CP, Kraehenbuhl JP, Bouzourene H, Michetti P: Gastric mucosal alpha(4)beta(7)-integrin-positive CD4 T lymphocytes and immune protection against Helicobacter infection in mice. Gastroenterology 2000;119:109–118.
[PubMed]
66.
Velin D, Bachmann D, Bouzourene H, Michetti P: Mast cells are critical mediators of vaccine-induced Helicobacter clearance in the mouse model. Gastroenterology 2005;129:142–155.
[PubMed]
67.
Wastling JM, Knight P, Ure J, Wright S, Thornton EM, Scudamore CL, Mason J, Smith A, Miller HR: Histochemical and ultrastructural modification of mucosal mast cell granules in parasitized mice lacking the beta-chymase, mouse mast cell protease-1. Am J Pathol 1998;153:491–504.
[PubMed]
68.
Jippo T, Lee YM, Ge Y, Kim DK, Okabe M, Kitamura Y: Tissue-dependent alteration of protease expression phenotype in murine peritoneal mast cells that were genetically labeled with green fluorescent protein. Am J Pathol 2001;158:1695–1701.
[PubMed]
69.
Geissler EN, Ryan MA, Housman DE: The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 1988;55:185–192.
[PubMed]
70.
Echtenacher B, Mannel DN, Hultner L: Critical protective role of mast cells in a model of acute septic peritonitis. Nature 1996;381:75–77.
[PubMed]
71.
Malaviya R, Ikeda T, Ross E, Abraham SN: Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNFalpha. Nature 1996;381:77–80.
[PubMed]
72.
Feger F, Varadaradjalou S, Gao Z, Abraham SN, Arock M: The role of mast cells in host defense and their subversion by bacterial pathogens. Trends Immunol 2002;23:151–158.
[PubMed]
73.
Godfraind C, Louahed J, Faulkner H, Vink A, Warnier G, Grencis R, Renauld JC: Intraepithelial infiltration by mast cells with both connective tissue-type and mucosal-type characteristics in gut, trachea, and kidneys of IL-9 transgenic mice. J Immunol 1998;160:3989–3996.
[PubMed]
74.
Abe T, Sugaya H, Ishida K, Khan WI, Tasdemir I, Yoshimura K: Intestinal protection against Strongyloides ratti and mastocytosis induced by administration of interleukin-3 in mice. Immunology 1993;80:116–121.
[PubMed]
75.
Ott VL, Cambier JC: Activating and inhibitory signaling in mast cells: new opportunities for therapeutic intervention? J Allergy Clin Immunol 2000;106:429–440.
[PubMed]
76.
Lantz CS, Boesiger J, Song CH, Mach N, Kobayashi T, Mulligan RC, Nawa Y, Dranoff G, Galli SJ: Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites. Nature 1998;392:90–93.
[PubMed]
77.
Lawrence CE: Is there a common mechanism of gastrointestinal nematode expulsion? Parasite Immunol 2003;25:271–281.
[PubMed]
78.
Cliffe LJ, Humphreys NE, Lane TE, Potten CS, Booth C, Grencis RK: Accelerated intestinal epithelial cell turnover: a new mechanism of parasite expulsion. Science 2005;308:1463–1465.
[PubMed]
79.
Kawakubo M, Ito Y, Okimura Y, Kobayashi M, Sakura K, Kasama S, Fukuda MN, Fukuda M, Katsuyama T, Nakayama J: Natural antibiotic function of a human gastric mucin against Helicobacter pylori infection. Science 2004;305:1003–1006.
[PubMed]
You do not currently have access to this content.